|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TTC33 |
Gene summary for TTC33 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TTC33 | Gene ID | 23548 |
| Gene name | tetratricopeptide repeat domain 33 | |
| Gene Alias | OSRF | |
| Cytomap | 5p13.1 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q6PID6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23548 | TTC33 | LZE4T | Human | Esophagus | ESCC | 2.33e-06 | 2.08e-01 | 0.0811 |
| 23548 | TTC33 | LZE5T | Human | Esophagus | ESCC | 2.34e-04 | 3.02e-01 | 0.0514 |
| 23548 | TTC33 | LZE8T | Human | Esophagus | ESCC | 3.88e-03 | 1.11e-01 | 0.067 |
| 23548 | TTC33 | LZE20T | Human | Esophagus | ESCC | 7.59e-06 | 1.20e-01 | 0.0662 |
| 23548 | TTC33 | LZE24T | Human | Esophagus | ESCC | 3.19e-09 | 1.30e-01 | 0.0596 |
| 23548 | TTC33 | LZE6T | Human | Esophagus | ESCC | 1.21e-11 | 4.70e-01 | 0.0845 |
| 23548 | TTC33 | P2T-E | Human | Esophagus | ESCC | 1.60e-08 | 1.96e-01 | 0.1177 |
| 23548 | TTC33 | P4T-E | Human | Esophagus | ESCC | 2.18e-11 | 2.27e-01 | 0.1323 |
| 23548 | TTC33 | P5T-E | Human | Esophagus | ESCC | 2.45e-04 | 7.67e-02 | 0.1327 |
| 23548 | TTC33 | P8T-E | Human | Esophagus | ESCC | 6.31e-08 | 1.82e-01 | 0.0889 |
| 23548 | TTC33 | P9T-E | Human | Esophagus | ESCC | 1.23e-05 | 6.05e-02 | 0.1131 |
| 23548 | TTC33 | P10T-E | Human | Esophagus | ESCC | 1.26e-20 | 2.72e-01 | 0.116 |
| 23548 | TTC33 | P11T-E | Human | Esophagus | ESCC | 1.84e-06 | 1.89e-01 | 0.1426 |
| 23548 | TTC33 | P12T-E | Human | Esophagus | ESCC | 6.28e-14 | 3.52e-01 | 0.1122 |
| 23548 | TTC33 | P15T-E | Human | Esophagus | ESCC | 2.82e-09 | 1.30e-01 | 0.1149 |
| 23548 | TTC33 | P16T-E | Human | Esophagus | ESCC | 1.52e-15 | 2.05e-01 | 0.1153 |
| 23548 | TTC33 | P17T-E | Human | Esophagus | ESCC | 2.97e-02 | 2.96e-01 | 0.1278 |
| 23548 | TTC33 | P20T-E | Human | Esophagus | ESCC | 2.71e-14 | 1.63e-01 | 0.1124 |
| 23548 | TTC33 | P21T-E | Human | Esophagus | ESCC | 5.27e-06 | 6.98e-02 | 0.1617 |
| 23548 | TTC33 | P22T-E | Human | Esophagus | ESCC | 8.85e-14 | 1.44e-01 | 0.1236 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TTC33 | SNV | Missense_Mutation | c.154N>T | p.Leu52Phe | p.L52F | Q6PID6 | protein_coding | deleterious(0.02) | benign(0.011) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| TTC33 | SNV | Missense_Mutation | c.294N>A | p.Met98Ile | p.M98I | Q6PID6 | protein_coding | tolerated(0.06) | benign(0.043) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| TTC33 | SNV | Missense_Mutation | c.443N>A | p.Arg148Gln | p.R148Q | Q6PID6 | protein_coding | deleterious(0.01) | possibly_damaging(0.808) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| TTC33 | deletion | Frame_Shift_Del | c.559delN | p.Ser187ValfsTer7 | p.S187Vfs*7 | Q6PID6 | protein_coding | TCGA-F4-6856-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Ancillary | leucovorin | CR | |||
| TTC33 | SNV | Missense_Mutation | novel | c.673N>T | p.Val225Phe | p.V225F | Q6PID6 | protein_coding | tolerated(0.68) | benign(0.06) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| TTC33 | SNV | Missense_Mutation | rs759828624 | c.404N>A | p.Arg135His | p.R135H | Q6PID6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| TTC33 | SNV | Missense_Mutation | rs144481517 | c.289N>A | p.Glu97Lys | p.E97K | Q6PID6 | protein_coding | deleterious(0.01) | possibly_damaging(0.853) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TTC33 | SNV | Missense_Mutation | c.496N>A | p.Glu166Lys | p.E166K | Q6PID6 | protein_coding | deleterious(0.01) | possibly_damaging(0.451) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
| TTC33 | SNV | Missense_Mutation | c.548N>T | p.Arg183Met | p.R183M | Q6PID6 | protein_coding | deleterious(0.01) | benign(0.029) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TTC33 | SNV | Missense_Mutation | novel | c.673G>A | p.Val225Ile | p.V225I | Q6PID6 | protein_coding | tolerated(0.47) | benign(0.018) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |